| Literature DB >> 31788240 |
Ginenus Fekadu1, Legese Chelkeba2, Tsegaye Melaku2, Busha Gamachu1, Mohammed Gebre1, Firomsa Bekele3, Getahun Fetensa4.
Abstract
OBJECTIVES: The number of stroke patients receiving recombinant tissue plasminogen activator (r-tPA) in developing world is extremely low. Pre-hospital delay, financial constraints and lack of infrastructure are the main barriers. Additionally, various medical, neurological and psychological complications are allied to stroke patients after the acute attack. Hence, the study was aimed to identify management protocols and encountered complications among stroke patients admitted to stroke unit of Jimma university medical center (JUMC). PATIENTS AND METHODS: Prospective observational study was conducted at stroke unit of JUMC from March 10 to July 10, 2017. All eligible consecutive stroke patients of ≥18 years were included. Data was entered to Epi data version 3.1 and analyzed using SPSS version 20.Entities:
Keywords: AHA/ASA, The American Heart Association/ American Stroke Association; Complications; Ethiopia; HS, Hemorrhagic stroke; IS, Ischemic stroke; JUMC, Jimma university medical center; Jimma; Management; SU, Stroke unit; Stroke; Treatment; WHO, World Health Organization; r-tPA, Recombinant tissue plasminogen activator
Year: 2019 PMID: 31788240 PMCID: PMC6880120 DOI: 10.1016/j.amsu.2019.11.003
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Socio-demographic characteristics among adult stroke patients admitted to stroke unit of JUMC from March 10 to July 10, 2017.
| Socio-demographic factors | Total patients (n = 116) | Ischemic stroke (n = 60) | Hemorrhagic stroke (n = 56) | P value | |
|---|---|---|---|---|---|
| Age (years) | Mean ± SD | 55.14 ± 14.04 | 57.38 ± 14.59 | 52.73 ± 13.14 | 0.187 |
| Sex | Male | 73 (62.9%) | 38 (63.3% | 35 (62.5% | 0.926 |
| Female | 43 (37.1%) | 22 (36.7%) | 21(37.5%) | ||
| Residence | Rural | 84 (72.4%) | 43 (71.7%) | 41 (73.2%) | 0.852 |
| Urban | 32 (27.6% | 17 (28.3%) | 15 (26.8%) | ||
| Marital status | Married | 104 (89.7%) | 54 (90.0%) | 50 (89.3%) | 0.575 |
| Widow | 11 (9.5%) | 5 (8.3%) | 6 (10.7%) | ||
| Divorced | 1 (0.9%) | 1 (1.7%) | 0 (0%) | ||
| Religion | Muslim | 71 (61.2%) | 40 (66.7%) | 31 (55.4% | 0.418 |
| Orthodox | 35(30.2%) | 15 (25.0%) | 20 (35.7%) | ||
| Protestant | 9 (7.8%) | 4 (6.7%) | 5 (8.9%) | ||
| Traditional belief | 1(0.9%) | 1 (1.7%) | – | ||
| Education status | No basic education | 42 (36.2%) | 20 (33.3%) | 22 (39.3%) | 0.642 |
| Informal education | 49 (42.2%) | 28 (46.7%) | 21 (37.5%) | ||
| Formal education | 25(21.6%) | 12(20%) | 13(23.2%) | ||
| Occupational status (over the last 1years) | Agriculture/farmer | 44 (37.9%) | 27 (45.0%) | 17(30.4%) | 0.264 |
| Homemaker/housewives | 41 (35.3% | 20 (33.3%) | 21 (37.5%) | ||
| Other professions | 31(26.7%) | 13(21.7%) | 18 (32.1%) | ||
SD: standard deviation.
* Silte, Yem, Tigire, Nuwer
Merchant, retired, government employee, other own business work, daily worker.
The in hospital complications among adult stroke patients admitted to stroke unit of JUMC from March 10 to July 10, 2017.
| Complications during hospital stay | Total | Ischemic stroke | Hemorrhagic stroke | P value | |
|---|---|---|---|---|---|
| Neurological complications (n = 53) | Brain edema/increase ICP | 35 (30.2%) | 5 (8.3%) | 30 (53.6%) | <0.001 |
| Swallowing difficulties/dysphagia | 13 (11.2%) | 5 (8.3%) | 8 (14.3%) | 0.315 | |
| Epileptic seizure | 10 (8.6%) | 6 (10.0%) | 4 (7.1%) | 0.585 | |
| Recurrent stroke/new stroke | 3 (2.6%) | 2 (3.3%) | 1 (1.8%) | 0.605 | |
| Delirium | 3 (2.6%) | 2 (3.3%) | 1 (1.8%) | 0.605 | |
| Central hyperthermia | 2 (1.7%) | 1 (1.7%) | 1 (1.8%) | 0.961 | |
| Parenchymal hemorrhage/ICH | 1 (0.9%) | 0 (0%) | 1 (1.8%) | – | |
| Medical complications (n = 82) | Urinary incontinence | 33 (28.4%) | 15 (25.0%) | 18 (32.1%) | 0.395 |
| Aspiration pneumonia | 23 (19.8%) | 9 (15.0%) | 14 (25.0%) | 0.181 | |
| Electrolyte disturbance | 20 (17.2%) | 8 (8.3%) | 12 (21.4%) | 0.252 | |
| Urinary tract infection | 17 (14.7%) | 11 (18.3%) | 6 (10.7%) | 0.251 | |
| Deep venous thrombosis (DVT) | 9 (7.8%) | 6 (10.0%) | 3 (5.4%) | 0.358 | |
| Acute renal failure | 8 (6.9%) | 4 (6.7%) | 4 (7.1%) | 0.919 | |
| Constipation | 6 (5.2%) | 5 (8.3%) | 1 (1.8%) | 0.148 | |
| Other hospital acquired infections | 5 (4.3%) | 3 (5.0%) | 2 (3.6%) | 0.706 | |
| Myocardial infarction (MI) | 4 (3.4%) | 3 (5.0%) | 1 (1.8%) | 0.364 | |
| Heart failure | 4 (3.4%) | 4 (6.7%) | 0 (0%) | 0.999 | |
| Atrial fibrillation | 3 (2.6%) | 3 (5.0%) | 0 (0%) | 0.999 | |
| Bed sores/decubitus ulcer/ | 2 (1.7%) | 1 (1.7%) | 1 (1.8%) | 0.961 | |
| Pulmonary embolism (PE) | 2 (1.7%) | 2 (3.3%) | 0 (0%) | 0.999 | |
| Lung infection (TB) | 1 (0.9%) | 1 (1.7%) | 0 (0%) | – | |
| Falls | 1 (0.9%) | 1 (1.7%) | 0 (0%) | – | |
| Phlebothrombosis | 1 (0.9%) | 0 (0%) | 1 (1.8%) | – | |
| DKA | 1 (0.9%) | 1 (1.7%) | 0 (0%) | – | |
DKA: diabetic keto acidosis, ICH: intracranial hemorrhage, ICP: intracranial pressure.
Approaches/protocols of stroke management among adult stroke patients admitted to stroke unit of JUMC from March 10 to July 10, 2017.
| Management protocols and medications | Total patients (=116) | Ischemic stroke (n = 60) | Hemorrhagic stroke (n = 56) | ||
|---|---|---|---|---|---|
| Pre-stroke medication (past medication history) (n = 61) | Diuretics | 33 (54.1%) | 22 (61.1%) | 11 (44.0%) | |
| ARB or ACEI | 19 (31.1) | 13 (36.1%) | 6 (24.0%) | ||
| Antiplatelet | 12 19.7%) | 10 (27.8%) | 2 (8.0%) | ||
| CCB | 12 (19.7%) | 5 (13.9%) | 7 (28.0%) | ||
| B-blocker | 8 (13.1%) | 8 (22.2%) | 0 (0%) | ||
| Statins | 6 (9.8%) | 5 (13.9%) | 1 (4.0%) | ||
| Anticoagulant | 5 (8.2%) | 5 (13.9%) | 0 (0%) | ||
| Antidiabetics | 4 (6.6%) | 3 (8.3%) | 1 (4.0%) | ||
| Unknown medications | 7 (11.5%) | 2 (5.6%) | 5 (20.0%) | ||
| Others | 13 (21.3%) | 9 (25.0%) | 4 (16.0%) | ||
| Medication given during hospitalization (n = 111) | Antiplatelets (n = 63) | Aspirin | 61 (96.8%) | 54 (96.4%) | 7 (100%) |
| Aspirin + clopidogrel | 2 (3.2%) | 2 (3.6%) | 0 (0%) | ||
| Statin (Atorvastatin) | 63 (54.3%) | 56 (93.3%) | 7 (12.5%) | ||
| ACE inhibitors (n = 41) | Enalapril | 27(65.9%) | 21 (84%) | 6 (37.5%) | |
| Captopril | 13 (31.7%) | 4 (16%) | 9 (56.3%) | ||
| Enalapril and captopril | 1 (2.4%) | 0 (0%) | 1 (6.3%) | ||
| Anticoagulants (n = 38) | Heparin | 30 (78.9%) | 22 (73.0%) | 8 (100%) | |
| Enoxaparin | 2 (5.3%) | 2 (6.7%) | 0 (0%) | ||
| Warfarin | 4 (10.5%) | 4 (13.0%) | 0(0%) | ||
| Heparin and warfarin | 1 (2.6%) | 1(3.3%) | 0 (0%) | ||
| Enoxaparin and warfarin | 1 (2.6%) | 1 (3.3%) | 0 (0%) | ||
| Osmotic diuretics (mannitol) | 35 (30.2%) | 5 (8.3%) | 30 (53.6%) | ||
| Thiazide diuretics/hydrochlorothiazide | 14 (12.1%) | 7 (11.7%) | 7 (12.5%) | ||
| Calcium channel blocker (n = 10) | Amlodipine | 5 (50.0%) | 1 (50.0%) | 4 (50.0%) | |
| Nifedipine | 4 (10.0%) | 1 (50.0%) | 3 (37.5%) | ||
| Nifedipine and amlodipine | 1 (10.0%) | 0 (0%) | 1 (12.5%) | ||
| Beta blockers (n = 9) | Atenolol | 1 (11.1%) | 0 (0%) | 1 (33.3%) | |
| propranolol | 1 (11.1%) | 1 (16.7%) | 0 (0%) | ||
| Metoprolol | 6 (66.7%) | 4 (66.7%) | 2 (66.7%) | ||
| Metoprolol and atenolol | 1 (11.1%) | 1 (16.7%) | 0 (0%) | ||
| Antidiabetics (insulin) | 8 (6.9%) | 4 (6.7%) | 4 (7.1%) | ||
| Loop diuretics/furosemide | 3 (2.6%) | 3 (5.0%) | 0 (0%) | ||
| Potassium sparing diuretics (spironolactone) | 1 (0.9%) | 1 (1.7%) | 0 (0%) | ||
| Miscellaneous medications | Antibiotics | 44 (37.9%) | 22 (36.7%) | 22 (39.3%) | |
| Antiulcers | 24 (20.7%) | 13 (21.7%) | 11 (19.6%) | ||
| Anticonvulsants | 10 (8.6%) | 6 (10.0%) | 4 (7.1%) | ||
| Maintenance fluid (MF) | 9 (7.8%) | 5 (8.3%) | 4 (7.1%) | ||
| Anti-pains | 6 (5.2%) | 1 (1.7%) | 5 (8.9%) | ||
| Laxatives | 6 (5.2%) | 5 (8.3%) | 1 (1.8%) | ||
| others | 14 (12.1%) | 9 (15.0%) | 5 (8.9%) | ||
| Other supportive (n = 115) | In-hospital rehabilitation therapy (bedside physiotherapy) | 115 (99.1%) | 60 (100%) | 55(98.2%) | |
| Salt free diet | 113 (97.4%) | 59 (98.3%) | 54 (96.4%) | ||
| Sugar free diet | 8 (6.4%) | 4 (6.7%) | 4 (7.1%) | ||
| Medications at discharge (n = 78) | Antihypertensive (n = 58) | ACEIS/ARBS | 26 (44.8%) | 17 (51.5%) | 9(36.0%) |
| Diuretics + ACEI | 10 (17.2%) | 7 (21.2%) | 3(12.0%) | ||
| Diuretics | 9 (15.5%) | 4(12.1%) | 5 (20.0%) | ||
| CCB | 6 (10.3%) | 2 (6.1%) | 4 (16.0%) | ||
| Diuretics + CCB | 3 (5.2%) | 0 (0%) | 3 (12.0%) | ||
| BB and ACEIs | 2 (3.4%) | 2 (6.1%) | 0 (0%) | ||
| CCB + ACEI | 1 (1.7%) | 0 (0%) | 1 (4.0%) | ||
| CCB + ACEIs + diuretics | 1 (1.7%) | 1 (3.0%) | 0 (0%) | ||
| Antiplatelet | 49 (42.2%) | 49 (81.7%) | 0 (0%) | ||
| Statins | 49 (42.2%) | 49 (81.7%) | 0 (0%) | ||
| Antibiotics | 7 (6.0%) | 3 (5.0%) | 4 (7.1%) | ||
| Antidiabetics | 6 (5.2%) | 3 (5.0%) | 3 (5.4%) | ||
| Anticoagulants | 3 (2.6%) | 3 (5.0%) | 0 (0%) | ||
| Others | 10 (8.6%) | 6 (10%) | 4 (7.1%) | ||
*ACEIs: angiotensin-converting enzyme inhibitors, ARBs: angiotensin II receptor blockers/antagonists, BB: beta blockers, CCB: Calcium channel blockers.